The Zacks Analyst Blog Berkshire Hathaway, The Home Depot, Pfizer and AMREP

For Immediate ReleasesChicago, IL – January 3, 2024 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Berkshire Hathaway Inc. (BRK.B), The Home Depot, Inc. HD, Pfizer Inc. PFE and AMREP Corp. AXR.Here are highlights from Friday’s Analyst Blog:Top Research Reports for Berkshire Hathaway, Home Depot and PfizerThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., The Home Depot, Inc. and Pfizer Inc., as well as a micro-cap stock AMREP Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Berkshire Hathaway’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+24.0% vs. +23.8%). The company is one of the largest property and casualty insurance companies with numerous diverse business activities. A strong cash position supports earnings-accretive bolt-on buyouts and is indicative of its financial flexibility.Continued insurance business growth fuels an increase in float, drives earnings and generates maximum return on equity. The non-insurance businesses have also been doing well in the last few years. The addition of Pilot Travel Centers (PTC) has strengthened its energy business. A sturdy capital level provides further impetus.However, exposure to cat loss induces earnings volatility and also affects underwriting results. Huge capital expenditures remain a headwind. With the demise of Charles Munger, uncertainty looms over the company's performance.(You can read the full research report on Berkshire Hathaway here >>>)Shares of Home Depot have outperformed the Zacks Retail - Home Furnishings industry over the past six months (+18.5% vs. +17.9%). The company’s stock prices is driven by a recovery in top-line trends supported by sales from the SRS acquisition. The company delivered better-than-expected sales and EPS in third-quarter fiscal 2024, with year-over-year sales growth fueled by gains in certain seasonal categories due to favorable weather and hurricane-related demand.Home Depot gains from its “One Home Depot” investment plan focused on expanding supply chain facilities, enhancing technology, and improving the digital experience. HD is also advancing efforts to build a robust Pro ecosystem.HD raised its sales and EPS view for fiscal 2024, citing strong third-quarter results and projected hurricane-related demand in Q4. However, comparable sales and EPS remain impacted by higher interest rates and ongoing macroeconomic uncertainties.(You can read the full research report on Home Depot here >>>)Pfizer’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-4.3% vs. +0.9%). The company’s revenues from Pfizer’s COVID-19 products are declining due to lower demand. Pfizer also expects a significant impact from the loss of patent exclusivity in the 2026-2030 period, as several of its key products face patent expirations.However, Pfizer’s non-COVID operational revenue growth improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches and newly acquired products from Seagen.Huge profits from its COVID products strengthened its cash position, which is being used to make acquisitions, increase dividends, buy back shares and reduce debt. Seagen’s acquisition has strengthened its position in oncology. Continued growth in non-COVID sales and significant cost-reducing measures should drive profit growth.(You can read the full research report on Pfizer here >>>)Shares of AMREP have outperformed the Zacks Real Estate - Development industry over the past year (+44.3% vs. -8.3%). This microcap company with market capitalization of $166.03 million has achieved impressive financial growth in fiscal 2025, with fiscal second-quarter revenues up 34.5% to $11.9 million and net income soaring 264.8% to $4 million. First-half revenues rose 61.9% to $30.9 million, driven by operational efficiency and favorable market conditions.Strategic land holdings in New Mexico position AMREP to benefit from rising housing demand amid easing monetary policies, declining mortgage rates and limited supply, supporting long-term growth. Favorable macro trends and resilient housing prices drive profitability.Risks include geographic concentration, market volatility, affordability challenges, reliance on the real estate market and elevated input costs. Regulatory changes, competition and economic uncertainty could impact performance, but AMREP’s operational efficiency and strong margins mitigate these risks.(You can read the full research report on AMREP here >>>)Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com                                     https://www.zacks.com                                                Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report The Home Depot, Inc. (HD): Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report AMREP Corporation (AXR): Get Free ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks